Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GENEDRIVE PLC Regulatory Filings 2016

Nov 11, 2016

7668_agm-r_2016-11-11_63a28392-baf2-4892-a8df-6785f89cb677.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0295P

Genedrive PLC

11 November 2016

RNS

For release: 11 November 2016

2016 Annual Report and AGM Notice

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, gives notice that copies of its 2016 Annual Report and Notice of the 2016 Annual General Meeting have been posted to shareholders. The AGM will be held at 11.00am on Wednesday, 30 November 2016 at the the Company's premises at The Innovation Centre, 48 Grafton Street, Manchester M13 9XX.In 2015/16.

Copies of these documents may be found on the Company's website (www.genedriveplc.com)

.

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                    +44 (0)161 989 0245

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                           +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner                                                                                         +44 (0)203 709 5700

Matthew Neal

Laura Thornton

[email protected] 

Notes to Editors

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need or point of care diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOABRBDBSSBBGLB